Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1377

Sort by

Sort Order Select

Journal Articles

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Blood (2024) 144 (1): 61–73.

https://doi.org/10.1182/blood.2024023930

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Samuel Urrutia, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2023-179979

Published: 2023

Journal Articles

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Wei-Ying Jen, Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Lewis Nasr, Courtney D. DiNardo, Marianne Zoghbi, Jovitta Jacob, Edith Roy, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2023-182982

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Blood (2023) 142 (Supplement 1): 233.

https://doi.org/10.1182/blood-2023-181880

Published: 2023

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2023-181379

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

Prospective Pharmacokinetic Evaluation of Venetoclax (VEN) in AML Demonstrates Significant and Variable Drug Interactions with Azole Antifungals That Increase Ven Exposure, Reduce Clearance, and Necessitate Re-Evaluation of Dose Adjustments

Jitesh Kawedia, Caitlin R Rausch, Xiaoqian Li, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Patrick K Reville, Nicholas J. Short, Elias Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2023-180491

Published: 2023

Journal Articles

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Blood (2023) 142 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2023-172882

Published: 2023

Journal Articles

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Blood (2023) 142 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2023-178061

Published: 2023

Journal Articles

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4228.

https://doi.org/10.1182/blood-2023-182841

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2023-182997

Published: 2023

Journal Articles

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Cedric Nasnas, Ejiroghene Mayor, Patrice Eric Nasnas, Wuliamatu Deen, Marianne Zoghbi, Jennifer Thankachan, Christopher Loiselle, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2023-188064

Published: 2023

Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood (2023) 142 (Supplement 1): 58.

https://doi.org/10.1182/blood-2023-182337

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

NARROW

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Prospective Pharmacokinetic Evaluation of Venetoclax (VEN) in AML Demonstrates Significant and Variable Drug Interactions with Azole Antifungals That Increase Ven Exposure, Reduce Clearance, and Necessitate Re-Evaluation of Dose Adjustments

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only